For patients with breast cancer, double mastectomy does not reduce mortality
the ONA take:
According to a new study published in The Journal of the American Medical Association, despite an increase in the number of women undergoing a double mastectomy for early-stage breast cancer, the procedure does not reduce the risk of mortality compared with breast-conserving therapy with radiation.
In the study, researchers identified 189,734 women diagnosed with early-stage unilateral breast cancer between 1998 and 2011 from the California Cancer Registry. Researchers followed the patients for an average of approximately 89 months.
They found that the rate of women with early-stage breast cancer undergoing double mastectomies rose from 2% to 12.3% in 1998 and 2011, respectively. Women aged 40 and over opting for the procedure rose from 3.6% to 33% in 1998 and 2011, respectively, making this group have the highest increase. Furthermore, the rate of women undergoing unilateral mastectomies decreased during this period.
In addition, the team found that women who chose to undergo a double mastectomy did not have a lower risk of mortality compared with women who underwent breast-conserving therapy plus radiation. Women who underwent a unilateral mastectomy were found to have a higher risk of death.
The procedure does not reduce the risk of mortality.
Having a double mastectomy for early-stage breast cancer is not linked to a lower risk of death than breast-conserving therapy plus radiation, but still there is an increase in the number of women undergoing the procedure. These are the findings of a new study published in JAMA.
This is not the first study to question the benefits of a double mastectomy, or bilateral mastectomy - the removal of both breasts - for breast cancer patients. Earlier this year, Medical News Today reported on a study published in JAMA Surgery claiming the procedure is unnecessary for the majority of women.
Sign Up for Free e-newsletters
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Patients and Caregivers Worry About Cost of Cancer Care
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- Opioid Shortage Influences How Cancer-Related Pain Is Managed by Inpatient Palliative Care Team
- Tumor Lysis Syndrome, Renal Failure Complicate Elotuzumab Therapy for Multiple Myeloma
- How to Help Patients at the End of Life and Their Loved Ones During the Holidays
- Real-World Prevalence of AEs With Immune Checkpoint Inhibitors for NSCLC Higher Than Reported in Trials
- Disparities Seen in Goals-of-Care Discussions With Minority vs Nonminority Patients
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|